Dasiglucagon (Zegalogue®): A Comprehensive Clinical and Pharmacological Monograph

Executive Summary & Drug Profile

Overview

Dasiglucagon is a next-generation, peptide-based antihypoglycemic agent developed for the emergency treatment of severe hypoglycemia in patients with diabetes mellitus.[1] As a glucagon analog, its fundamental mechanism is to rapidly elevate blood glucose levels by stimulating the liver to release stored glucose.[1] The primary innovation of dasiglucagon lies in its molecular design, which confers enhanced physicochemical stability in an aqueous solution. This property allows it to be formulated as a ready-to-use product, available in a pre-filled syringe and an auto-injector, thereby eliminating the complex and error-prone reconstitution process required for traditional glucagon emergency kits.[4]

Clinical evidence from a robust Phase 3 development program has established its efficacy and safety. In pivotal trials, a single subcutaneous injection of dasiglucagon demonstrated statistical superiority to placebo and clinical comparability to reconstituted glucagon, achieving a median time to plasma glucose recovery of 10 minutes.[5] The safety profile is well-characterized and consistent with the known effects of glucagon, with the most common adverse events being nausea and vomiting.[5] Approved by major regulatory bodies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and marketed under the brand name Zegalogue®, dasiglucagon represents a significant advancement in emergency diabetes care, offering a rapid, effective, and user-friendly solution for a life-threatening condition.[10]

Chemical and Physicochemical Properties

Dasiglucagon is classified as a biotech therapeutic, specifically a protein-based hormone analog.[4] It is a synthetic peptide composed of 29 amino acids, mirroring the length of endogenous human glucagon.[1] The molecule's defining feature, and the foundation of its clinical utility, is the strategic substitution of seven amino acids relative to the native glucagon sequence.[1]

This molecular engineering was purposefully undertaken to overcome the inherent instability of human glucagon in aqueous solutions. Native glucagon has a high propensity to form amyloid fibrils and aggregate at physiological pH, rendering it unsuitable for a stable, liquid formulation and necessitating its supply as a lyophilized powder that requires reconstitution immediately before use.[5] The seven substitutions in dasiglucagon were designed to increase electrostatic repulsion and remove amino acids critical for the aggregation process, resulting in markedly improved solubility (≥ 20 mg/mL) and physicochemical stability.[6] This stability is maintained even under stressed conditions, such as elevated temperatures and agitation, which cause native glucagon to fibrillate within hours.[6]

The direct consequence of this enhanced molecular stability is the feasibility of a ready-to-use, pre-mixed aqueous formulation. This innovation transforms the treatment paradigm for severe hypoglycemia. It replaces a multi-step, high-stress procedure for caregivers—which studies have shown has a high failure rate in real-world settings—with a simple, single-step injection.[5] Thus, the chemical modification of the peptide backbone is not merely a pharmaceutical refinement but the foundational enabler of the drug's primary clinical advantage: speed, reliability, and ease of use in an emergency. The one-letter amino acid sequence of dasiglucagon is H-His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Aib-Ala-Arg-Ala-Glu-Glu-Phe-Val-Lys-Trp-Leu-Glu-Ser-Thr-OH, where the non-standard amino acid Aib (α-aminoisobutyric acid) is one of the key stabilizing substitutions.[17]

Identifier / Property	Details	Source(s)
Generic Name	Dasiglucagon	4
Brand Name (US & EU)	Zegalogue®	9
DrugBank ID	DB15226	4
CAS Number	1544300-84-6	9
Type / Class	Biotech, Protein-Based Therapy, Hormone, Glucagon Analog	1
Chemical Formula	C152​H222​N38​O50​	4
Molecular Weight	3381.66 g·mol⁻¹ / 3382.0 Da (anhydrous, free-base)	4
Amino Acid Sequence	HSQGTFTSDYSKYLDXARAEEFVKWLEST (X = Aib)	17
ATC Code	H04AA02	1

Comprehensive Pharmacological Profile

Mechanism of Action

Dasiglucagon exerts its therapeutic effect by functioning as a potent glucagon receptor agonist.[1] Its mechanism of action is identical to that of endogenous glucagon, and in vitro studies confirm that its potency at the human glucagon receptor is similar to that of the native hormone.[2] The primary biological target is the glucagon receptor, a member of the G-protein coupled receptor (GPCR) superfamily, which is expressed at high density on the surface of hepatocytes in the liver.[3]

The binding of dasiglucagon to the hepatic glucagon receptor initiates a conformational change in the receptor, which in turn activates associated intracellular signaling proteins, specifically the G proteins Gsα​ and Gq​.[4] This activation triggers a downstream signaling cascade. The activated

Gsα​ subunit stimulates the enzyme adenylate cyclase, which catalyzes the conversion of adenosine triphosphate (ATP) to the second messenger cyclic adenosine monophosphate (cAMP).[4]

The resultant increase in intracellular cAMP levels activates protein kinase A (PKA), which then phosphorylates and activates key enzymes involved in hepatic glucose production. This leads to the stimulation of two critical metabolic pathways:

1. Glycogenolysis: The rapid breakdown of stored glycogen into glucose-6-phosphate, which is then converted to free glucose and released into the bloodstream.[1]
2. Gluconeogenesis: The synthesis of new glucose from non-carbohydrate precursors, such as amino acids and lactate.[4]

The physiological effect—a rapid increase in blood glucose concentration—is primarily driven by glycogenolysis. This fact underscores a critical clinical limitation: the efficacy of dasiglucagon is entirely dependent on the presence of adequate hepatic glycogen stores. In physiological states characterized by depleted glycogen reserves, such as prolonged fasting, starvation, adrenal insufficiency, or chronic hypoglycemia, dasiglucagon will be ineffective. In these situations, the administration of exogenous glucose is required to treat severe hypoglycemia.[2]

Pharmacodynamics

The pharmacodynamic effect of dasiglucagon is a rapid, dose-dependent, and robust elevation of plasma glucose concentrations under both normal and hypoglycemic conditions.[1] Clinical studies in patients with type 1 diabetes mellitus (T1DM) have quantified this response following a standard 0.6 mg subcutaneous dose.

In adult patients with T1DM, administration of dasiglucagon resulted in a mean increase in plasma glucose from baseline of 168 mg/dL at 90 minutes post-injection.[1] In pediatric patients with T1DM (aged 7 to 17 years), the response was similarly potent, with a mean glucose increase of 162 mg/dL observed at 60 minutes post-administration.[1]

Comparative pharmacodynamic studies against reconstituted glucagon (GlucaGen) have provided further characterization. While the initial speed of glucose elevation is similar between the two agents (e.g., median time to achieve a plasma glucose level of ≥70 mg/dL is approximately 6-10 minutes for both), dasiglucagon has been shown to produce a longer-lasting and greater overall hyperglycemic effect.[6] This is evidenced by a significantly higher Area Under the Effect Curve (AUE) for plasma glucose with dasiglucagon at corresponding doses, indicating a more sustained physiological response.[15]

Pharmacokinetics: ADME Profile

The pharmacokinetic profile of dasiglucagon has been characterized through clinical trials, defining its absorption, distribution, metabolism, and elimination (ADME) properties following subcutaneous administration.

Absorption: After subcutaneous injection, dasiglucagon is rapidly absorbed, with plasma concentrations increasing in a dose-proportional manner across the tested range of 0.1 mg to 1.0 mg.[23] The time to reach maximum plasma concentration (

Tmax​) exhibits a notable difference between age groups. In adults, the median Tmax​ is approximately 35 minutes.[3] In pediatric patients (aged 6 to 17 years), absorption is faster, with a median

Tmax​ of approximately 21 minutes.[2] For the approved 0.6 mg dose, the mean peak plasma concentration (

Cmax​) is approximately 5110 pg/mL in adults and 3920 pg/mL in the pediatric population.[3] The use of a single fixed dose across a wide range of body weights is supported by pharmacokinetic modeling, which indicates that the higher total drug exposure seen in individuals with lower body weight is partially offset by factors such as higher clearance and lower bioavailability in the pediatric population.[5] This ensures a consistent and effective pharmacodynamic response despite variations in body size.

Distribution: Dasiglucagon distributes into the tissues, with a mean apparent volume of distribution (Vd​) ranging from 47 L to 57 L after subcutaneous administration.[3] This value suggests that the drug is not confined solely to the vascular compartment.

Metabolism: The metabolic clearance of dasiglucagon mirrors that of endogenous glucagon. It is a peptide that undergoes proteolytic degradation into its constituent amino acids and smaller peptides.[2] This breakdown occurs primarily in the blood, liver, and kidneys.[3]

Elimination: The elimination of dasiglucagon from the body is rapid. The terminal elimination half-life (t1/2​) is consistently reported to be approximately 30 minutes in both adult and pediatric populations.[2]

Bioavailability: A dedicated clinical trial comparing subcutaneous versus intravenous administration was conducted to determine the absolute bioavailability of dasiglucagon. The results showed that following a subcutaneous injection into the abdomen, the absolute bioavailability is approximately 51%.[27]

Pharmacokinetic Parameter	Adults (≥18 years)	Pediatrics (6-17 years)	Source(s)
Tmax​ (Median)	~35 minutes	~21 minutes	3
Cmax​ (Mean, 0.6 mg dose)	~5110 pg/mL	~3920 pg/mL	3
Volume of Distribution (Vd​)	47 L to 57 L	Not specified	3
Elimination Half-life (t1/2​)	~30 minutes	~30 minutes	3
Absolute Bioavailability (SC)	~51%	Not specified	27

Clinical Efficacy and Development Program

Overview of Clinical Trials

The clinical development of dasiglucagon followed a structured pathway designed to establish its safety, pharmacokinetics, and efficacy as a treatment for severe hypoglycemia. The program began with Phase 1 trials in healthy volunteers to assess safety, tolerability, and bioavailability following both subcutaneous and intravenous administration.[25] These were followed by Phase 2 trials in patients with T1DM, which provided crucial dose-ranging information and directly compared the pharmacodynamic and pharmacokinetic profiles of dasiglucagon against marketed reconstituted glucagon.[25]

The cornerstone of the development program was a series of three pivotal, multicenter, randomized, double-blind, placebo-controlled Phase 3 trials conducted in both adult and pediatric (aged 6-17 years) populations with T1DM.[5] The decision to focus the pivotal trials on patients with T1DM was a deliberate methodological choice to eliminate the potential confounding effects of endogenous insulin production, which can be variable in patients with type 2 diabetes mellitus (T2DM).[33] However, because the mechanism of action—stimulating hepatic glucose release—is independent of diabetes type, the efficacy findings are considered applicable to all patients with diabetes who have sufficient hepatic glycogen.[33]

Pivotal Phase 3 Trial Findings

The data from the Phase 3 trials provided unequivocal evidence of dasiglucagon's efficacy and formed the basis for its regulatory approvals worldwide.[12] In these studies, participants underwent controlled, insulin-induced hypoglycemia and were then treated with a single 0.6 mg subcutaneous dose of dasiglucagon, placebo, or a reference dose of reconstituted glucagon.[5]

Primary Efficacy Endpoint: The primary endpoint for these trials was the time to plasma glucose (PG) recovery, rigorously defined as the first observed increase in plasma glucose of ≥20 mg/dL from the point of hypoglycemia without the need for rescue intravenous glucose administration.[5]

Efficacy versus Placebo: Dasiglucagon demonstrated profound and statistically significant superiority over placebo. Across all pivotal trials, the median time to achieve PG recovery in the dasiglucagon group was consistently 10 minutes. In stark contrast, the median recovery time for patients receiving placebo was 30 to 40 minutes, a clinically and statistically significant difference (P<0.001).[5]

Comparison to Reconstituted Glucagon: Reconstituted glucagon was included in the trials as an active reference, not for a formal non-inferiority or superiority comparison. The results showed that the efficacy of dasiglucagon was clinically comparable to this established standard of care. The median time to recovery for the reconstituted glucagon group was 10 to 12 minutes.[5] This finding is particularly compelling because the reported time for reconstituted glucagon in these controlled trials does not account for the time required for its preparation. In a real-world emergency, the multi-step reconstitution process introduces a significant delay and potential for error that is entirely eliminated by the ready-to-use format of dasiglucagon. Therefore, while the measured recovery times are similar, the true, "real-world" time from recognition of hypoglycemia to therapeutic effect is substantially shorter for dasiglucagon.[5]

Treatment Success Rates: The speed of recovery was matched by a high rate of treatment success. In the pivotal adult trial, 99% of participants treated with dasiglucagon achieved PG recovery within 15 minutes of injection. This was vastly superior to the 2% success rate observed with placebo and similar to the 95% rate seen with reconstituted glucagon.[7] In the pediatric trial, 100% of participants in both the dasiglucagon and glucagon arms achieved recovery within 20 minutes, compared to only 18% of those on placebo.[5]

Efficacy Outcome	Dasiglucagon (0.6 mg)	Placebo	Reconstituted Glucagon (1 mg)	Source(s)
Median Time to PG Recovery	10 minutes	30-40 minutes	10-12 minutes	5
% of Patients Recovered within 15 min	99%	2%	95%	7
Statistical Significance (vs. Placebo)	P<0.001	N/A	N/A	5

Safety, Tolerability, and Risk Management

Adverse Reactions Profile

The safety and tolerability of dasiglucagon have been extensively evaluated throughout its clinical development program. The overall safety profile is well-characterized and is consistent with the known class effects of glucagon and its analogs, with adverse events being predominantly gastrointestinal in nature and generally transient.[5]

The most common adverse reactions reported in clinical trials (occurring in ≥2% of patients) are detailed below. It is noteworthy that the incidence of nausea and vomiting was observed to be higher in the adolescent subgroup (12-17 years) compared to younger children and adults.[3]

Adverse Reaction	Adults (%)	Pediatrics (6-17 years) (%)	Source(s)
Nausea	57	65	3
Vomiting	25	50	3
Headache	11	10	3
Diarrhea	5	<2	3
Injection Site Pain	2	5	3

Other less frequently reported adverse reactions include cardiovascular effects such as transient hypertension, hypotension, bradycardia, palpitations, and presyncope.[21] Hypersensitivity reactions, a known risk for all glucagon products, have been reported and may range from a generalized rash to, in rare cases, anaphylactic shock with respiratory distress and hypotension.[2] Patients should be advised to seek immediate medical attention if they experience symptoms of a serious allergic reaction.[36]

Contraindications

The use of dasiglucagon is strictly contraindicated in two specific medical conditions due to the high risk of severe, paradoxical adverse events.[2]

1. Pheochromocytoma: This is a rare tumor of the adrenal medulla that secretes high levels of catecholamines (e.g., epinephrine, norepinephrine). Glucagon products, including dasiglucagon, can directly stimulate these tumors to release massive amounts of catecholamines into circulation. This can precipitate a life-threatening hypertensive crisis, characterized by a sudden and substantial increase in blood pressure.[2] If a previously undiagnosed pheochromocytoma is suspected after administration (due to a marked rise in blood pressure), intravenous phentolamine mesylate (5-10 mg) can be used to lower blood pressure.[2]
2. Insulinoma: This is a tumor of the beta cells of the pancreas that autonomously secretes excessive amounts of insulin. Administering dasiglucagon to a patient with an insulinoma creates a dangerous paradoxical effect. The drug will initially cause a rise in blood glucose as expected. However, this hyperglycemia acts as a powerful stimulus for the insulinoma, causing it to release an exaggerated and uncontrolled surge of insulin. This overwhelming insulin release will rapidly drive blood glucose levels down, leading to subsequent and potentially more severe hypoglycemia than the initial event.[2] If this occurs, the patient must be treated with oral or intravenous glucose.[2]

Warnings and Precautions

In addition to the absolute contraindications, there are several important warnings and precautions for the use of dasiglucagon.

• Lack of Efficacy in Patients with Decreased Hepatic Glycogen: The antihypoglycemic effect of dasiglucagon is entirely dependent on the liver's ability to release glucose from its glycogen stores. Therefore, the drug will be ineffective in patients whose glycogen reserves are depleted. This includes individuals in states of prolonged fasting or starvation, those with adrenal insufficiency, or patients with chronic hypoglycemia. These patient populations should be treated with exogenous glucose rather than dasiglucagon.[2]
• Hypersensitivity and Allergic Reactions: As with other glucagon products, there is a risk of allergic reactions. Patients and caregivers should be aware of the signs of a serious reaction, such as rash, hives, difficulty breathing, or hypotension, and seek immediate medical help if they occur.[2]
• Immunogenicity: The potential for the development of anti-drug antibodies (ADAs) exists. In clinical trials, treatment-emergent ADAs were detected in less than 1% of patients treated with dasiglucagon. While no adverse effects on safety or efficacy were observed in these individuals, the long-term clinical significance of ADA development is not fully established.[2]

Drug-Drug Interactions

There are three clinically significant drug-drug interactions that require caution and monitoring when dasiglucagon is administered.

• Beta-blockers: Patients taking beta-blockers may experience a transient increase in both pulse and blood pressure following dasiglucagon administration. Dasiglucagon can stimulate the release of catecholamines, which have both alpha- and beta-adrenergic effects. In the presence of beta-blockade, the alpha-adrenergic effects (vasoconstriction) may be unopposed, leading to a temporary rise in blood pressure and a reflex increase in heart rate.[3]
• Indomethacin: In patients taking the non-steroidal anti-inflammatory drug (NSAID) indomethacin, dasiglucagon may lose its ability to raise blood glucose. In some cases, it may even produce a paradoxical hypoglycemic effect. The precise mechanism is not fully elucidated but is thought to involve interference with the cAMP signaling pathway.[3]
• Warfarin: Dasiglucagon may potentiate the anticoagulant effect of warfarin, potentially increasing the risk of bleeding. Patients on concomitant therapy should be monitored accordingly.[3]

Regulatory and Commercial Trajectory

Global Regulatory Approvals

Dasiglucagon has successfully navigated the regulatory pathways in major global markets, securing approval for its primary indication.

• United States (U.S. Food and Drug Administration - FDA): Dasiglucagon was first approved by the FDA on March 22, 2021. It is marketed under the brand name Zegalogue® and is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and older.[4]
• European Union (European Medicines Agency - EMA): Following the submission of a Marketing Authorization Application (MAA) by Zealand Pharma, the EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval on May 31, 2024.[41] The European Commission (EC) subsequently granted a marketing authorization valid throughout the European Union on July 24, 2024, also under the brand name Zegalogue®.[11]

Commercialization and Strategic Partnerships

The commercial journey of dasiglucagon illustrates a common strategic dynamic between innovative biotechnology companies and established pharmaceutical corporations.

• Originator and Initial Developer: Dasiglucagon was discovered and developed by Zealand Pharma A/S, a biotechnology company based in Copenhagen, Denmark, specializing in peptide-based medicines.[41] After securing FDA approval, Zealand Pharma launched Zegalogue® in the U.S. in June 2021.[46]
• Global Licensing and Development Agreement: Despite a successful clinical program, Zealand Pharma faced challenges in the commercial launch, competing in a crowded diabetes market dominated by large pharmaceutical companies. Initial sales did not meet expectations, prompting a strategic shift.[47] In September 2022, Zealand Pharma announced it had entered into a global license and development agreement with Novo Nordisk A/S, a world leader in diabetes care.[41]
• Terms and Rationale of the Partnership: Under the terms of the agreement, Novo Nordisk assumed responsibility for the global commercialization of Zegalogue®.[46] In return, Zealand Pharma received an upfront payment of DKK 25 million and became eligible for a series of development, regulatory, manufacturing, and sales-based milestone payments (potentially totaling up to DKK 290 million), in addition to tiered royalties on worldwide net sales.[46] Zealand Pharma retained responsibility for certain ongoing development and regulatory activities, including completing the MAA submission to the EMA.[41]

This partnership is a clear example of strategic synergy. For Zealand Pharma, it de-risked the commercialization process, allowing the company to monetize a key asset and refocus on its core competency of research and development. For Novo Nordisk, the agreement represented a valuable portfolio expansion, adding a best-in-class, next-generation rescue therapy to its comprehensive suite of diabetes treatments and reinforcing its market leadership position.[46]

Therapeutic Context and Comparative Analysis

Dasiglucagon vs. Traditional Reconstituted Glucagon

The primary value proposition of dasiglucagon is best understood in comparison to the traditional glucagon emergency kits (e.g., GlucaGen®) that were the standard of care for decades.

• Efficacy: In controlled clinical trial settings, the core efficacy—the median time to restore blood glucose levels—is comparable, with both dasiglucagon and reconstituted glucagon working in approximately 10-12 minutes.[7]
• Usability and Formulation: This is the defining point of differentiation. Traditional kits contain glucagon as a lyophilized powder in one vial and a diluent (sterile water) in another. Before administration, a caregiver must perform a complex, multi-step process: draw the diluent into a syringe, inject it into the powder vial, swirl to dissolve, draw the reconstituted solution back into the syringe, and then administer the injection.[5] This process is notoriously difficult and stressful, especially for an untrained individual during a medical emergency, and studies indicate successful administration rates can be as low as 6-56%.[16] Dasiglucagon, as a stable, pre-mixed solution in an auto-injector or pre-filled syringe, reduces this entire process to a single step, dramatically increasing the likelihood of successful and timely administration (rates of 94-100% for ready-to-use products).[16]
• Dosing: Dasiglucagon employs a simple, fixed 0.6 mg dose for all patients aged 6 years and older. In contrast, traditional glucagon dosing for children is often weight-based, adding another layer of complexity and potential for error during an emergency.[50]

Dasiglucagon vs. Other Ready-to-Use Formulations (Gvoke®, Baqsimi®)

Dasiglucagon entered a market with other innovative, ready-to-use competitors. The choice between these next-generation agents is not one of clear superiority but rather a nuanced decision based on specific product attributes and patient characteristics. All three products—Zegalogue®, Gvoke®, and Baqsimi®—are highly effective, with treatment success rates exceeding 98%, and all represent a major improvement over reconstitution kits.[51]

The key differences lie in their molecular composition, route of administration, and approved patient populations.

• Active Molecule: Zegalogue® contains dasiglucagon, a glucagon analog. Gvoke® and Baqsimi® both contain native human glucagon, but in novel, stable formulations.[50]
• Route of Administration: Zegalogue® and Gvoke® are administered via subcutaneous injection. Baqsimi® is a needle-free option, delivered as a dry powder spray into a single nostril, which may be preferred for patients with needle phobia.[50]
• Approved Age: There are important differences in the approved pediatric age ranges. Gvoke® is approved for patients aged 2 years and older, Baqsimi® for those 4 years and older, and Zegalogue® for those 6 years and older. This gives Gvoke® and Baqsimi® an advantage for treating severe hypoglycemia in very young children.[50]
• Dosing Regimen: Zegalogue® and Baqsimi® utilize a simple, fixed-dose regimen for all approved ages. Gvoke® dosing is weight-based for its pediatric population, which may be perceived as more complex.[50]
• Pharmacodynamics: An indirect treatment comparison suggests that while all three are effective, Baqsimi® may result in a statistically significantly lower peak blood glucose level compared to the injectable options. This could be viewed as a potential advantage in helping to re-establish normal blood sugar levels without causing a significant hyperglycemic overshoot.[52]

Ultimately, the clinical decision between these modern agents depends on a careful consideration of these trade-offs, tailored to the individual patient's age, preferences (e.g., needle aversion), and the caregiver's comfort level with different administration methods.

Attribute	Zegalogue®	Gvoke®	Baqsimi®
Active Molecule	Dasiglucagon (Glucagon Analog)	Glucagon (Native)	Glucagon (Native)
Route of Administration	Subcutaneous Injection (Auto-injector, Syringe)	Subcutaneous Injection (Auto-injector, Syringe, Vial)	Intranasal Powder (Single-use device)
Approved Age	≥ 6 years	≥ 2 years	≥ 4 years
Dosing	Fixed 0.6 mg dose	Age/weight-based for pediatrics	Fixed 3 mg dose
Key Advantage	Analog stability, fixed-dose simplicity	Broadest pediatric age indication for an injectable	Needle-free administration

Future Directions and Investigational Uses

The development of dasiglucagon extends beyond its approved indication for severe hypoglycemia, with active investigation into other therapeutic areas where its stable, pump-compatible properties could be beneficial.

• Congenital Hyperinsulinism (CHI): Dasiglucagon is in late-stage development for the management of CHI, a rare and serious genetic disorder of the pancreas that causes unregulated insulin secretion, leading to persistent and severe hypoglycemia in infants and children.[25] The therapeutic goal is to use a continuous subcutaneous infusion of dasiglucagon via a pump to counteract the excess insulin and stabilize blood glucose levels, potentially reducing the need for frequent feedings, intensive hospital care, or major surgery (pancreatectomy).[32] Dasiglucagon has received Orphan Drug Designation for the treatment of CHI from both the FDA and the EMA, recognizing the significant unmet need in this population.[32] While Phase 3 trials have been completed and regulatory submissions made, the FDA issued a complete response letter in October 2024 requesting additional data analysis to support its use for extended periods, indicating that further evaluation is needed.[43]
• Bi-hormonal Artificial Pancreas Systems: The exceptional stability of dasiglucagon in an aqueous solution makes it an ideal candidate for use in next-generation, dual-hormone automated insulin delivery systems, often referred to as a "bionic" or "artificial" pancreas.[6] These closed-loop systems use a continuous glucose monitor to autonomously control a pump that can deliver both insulin (to lower high blood sugar) and glucagon (to raise low blood sugar). The instability of previous glucagon formulations was a major barrier to this technology. Dasiglucagon's stability allows it to be stored in a pump cartridge for extended periods, enabling the system to deliver preventative micro-doses of glucagon to avert impending hypoglycemia, thereby achieving much tighter and safer glycemic control.[30] Clinical trials are ongoing to evaluate dasiglucagon in this setting, such as in collaboration with Beta Bionics for its iLet™ system.[30]

Synthesis and Expert Conclusion

Dasiglucagon (Zegalogue®) represents a paragon of rational drug design, where a fundamental improvement in molecular science has been successfully translated into a tangible and significant clinical benefit. The core innovation—the engineering of a stable glucagon analog through seven amino acid substitutions—directly addresses the most critical failing of traditional glucagon therapy: its instability and consequent need for a complex, error-prone reconstitution process. By eliminating this barrier, dasiglucagon provides patients with diabetes and their caregivers a tool that is not only effective but, crucially, reliable and simple to use during a life-threatening hypoglycemic emergency.

The comprehensive clinical trial program has unequivocally established its rapid efficacy, demonstrating a median time to blood glucose recovery of 10 minutes, which is clinically on par with reconstituted glucagon but without the latter's hidden preparation delay. Its safety profile is well-defined, predictable, and consistent with the glucagon drug class, allowing for confident clinical use within its specified contraindications and warnings.

In the current therapeutic landscape, dasiglucagon is positioned as a leading option among a new generation of ready-to-use rescue therapies. While it faces competition from other novel formulations, its unique profile—as a stable analog with a simple, fixed-dose regimen—secures its distinct place in the clinical armamentarium. The strategic commercial partnership with Novo Nordisk leverages global expertise in diabetes care, ensuring that this important therapeutic advancement can achieve broad patient access. Furthermore, its ongoing investigation for rare diseases like congenital hyperinsulinism and its potential as a key component in bi-hormonal artificial pancreas systems highlight its promise as a versatile platform molecule.

In conclusion, dasiglucagon is a landmark achievement in the management of severe hypoglycemia. It effectively mitigates the long-standing challenges of emergency glucagon administration, offering a solution that is rapid, potent, and, most importantly, dependable when moments matter most.

Works cited

1. Dasiglucagon | C152H222N38O50 | CID 126961379 - PubChem, accessed September 15, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Dasiglucagon
2. Dasiglucagon Monograph for Professionals - Drugs.com, accessed September 15, 2025, https://www.drugs.com/monograph/dasiglucagon.html
3. This label may not be the latest approved by FDA. For current ..., accessed September 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214231s000lbl.pdf
4. Dasiglucagon: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 15, 2025, https://go.drugbank.com/drugs/DB15226
5. Dasiglucagon, a next‐generation ready‐to‐use glucagon analog, for treatment of severe hypoglycemia in children and adolescents with type 1 diabetes: Results of a phase 3, randomized controlled trial - PMC - PubMed Central, accessed September 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8361970/
6. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog | Diabetes Care, accessed September 15, 2025, https://diabetesjournals.org/care/article/41/3/531/36652/Pharmacokinetic-and-Pharmacodynamic
7. Dasiglucagon Demonstrates Superiority to Placebo for Severe Hypoglycemia in Phase 3 Trial | HCPLive, accessed September 15, 2025, https://www.hcplive.com/view/dasiglucagon-demonstrates-superiority-severe-hypoglycemia-phase-3-trial
8. Dasiglucagon—A Next-Generation Glucagon Analog for Rapid and Effective Treatment of Severe Hypoglycemia: Results of Phase 3 Randomized Double-Blind Clinical Trial | Diabetes Care, accessed September 15, 2025, https://diabetesjournals.org/care/article-abstract/44/6/1361/138706
9. Dasiglucagon - Wikipedia, accessed September 15, 2025, https://en.wikipedia.org/wiki/Dasiglucagon
10. Zegalogue (dasiglucagon) FDA Approval History - Drugs.com, accessed September 15, 2025, https://www.drugs.com/history/zegalogue.html
11. In which countries is Dasiglucagon approved? - Patsnap Synapse, accessed September 15, 2025, https://synapse.patsnap.com/article/in-which-countries-is-dasiglucagon-approved
12. Zegalogue | European Medicines Agency (EMA), accessed September 15, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/zegalogue
13. The effectiveness and safety of dasiglucagon in emergency medicine - Via Medica Journals, accessed September 15, 2025, https://journals.viamedica.pl/disaster_and_emergency_medicine/article/view/101658/80827
14. Dasiglucagon Is a Novel Stable Glucagon Analog With Rapid Glucose Response Following Subcutaneous Injection in Hypoglycemic Rats | Request PDF - ResearchGate, accessed September 15, 2025, https://www.researchgate.net/publication/348883830_Dasiglucagon_Is_a_Novel_Stable_Glucagon_Analog_With_Rapid_Glucose_Response_Following_Subcutaneous_Injection_in_Hypoglycemic_Rats
15. Dasiglucagon in severe hypoglycemia: a profile of its use, accessed September 15, 2025, https://d-nb.info/1261138600/34
16. Dasiglucagon demonstrates reduced costs in the treatment of severe hypoglycemia in a budget impact model, accessed September 15, 2025, https://www.jmcp.org/doi/full/10.18553/jmcp.2022.28.4.461
17. Dasiglucagon,CAS :1544300-84-6 - Ruixibiotech, accessed September 15, 2025, https://www.ruixibiotech.com/pts/dasiglucagon
18. Dasiglucagon - CPC Scientific, accessed September 15, 2025, https://cpcscientific.com/products/catalog-peptides/GLUC-020/
19. Dasiglucagon | TargetMol, accessed September 15, 2025, https://www.targetmol.com/compound/dasiglucagon
20. go.drugbank.com, accessed September 15, 2025, https://go.drugbank.com/drugs/DB15226#:~:text=Dasiglucagon%20is%20an%20analog%20of,receptors%20expressed%20throughout%20the%20body.
21. Dasiglucagon | Drug Lookup | Pediatric Care Online - AAP Publications, accessed September 15, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/6314/Dasiglucagon
22. Zegalogue (dasiglucagon) dosing, indications, interactions, adverse effects, and more, accessed September 15, 2025, https://reference.medscape.com/drug/zegalogue-dasiglucagon-4000161
23. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog - PubMed, accessed September 15, 2025, https://pubmed.ncbi.nlm.nih.gov/29273578/
24. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog | Request PDF - ResearchGate, accessed September 15, 2025, https://www.researchgate.net/publication/322022568_Pharmacokinetic_and_Pharmacodynamic_Characteristics_of_Dasiglucagon_a_Novel_Soluble_and_Stable_Glucagon_Analog
25. Dasiglucagon | Glucagon Analog - MedchemExpress.com, accessed September 15, 2025, https://www.medchemexpress.com/dasiglucagon.html
26. 356-P: Population Pharmacokinetic Modeling of Dasiglucagon in Subjects with Type 1 Diabetes Mellitus, accessed September 15, 2025, https://diabetesjournals.org/diabetes/article-xml/70/Supplement_1/356-P/140098
27. Pharmacokinetic (PK) and pharmacodynamic response to intravenous (IV)... | Download Scientific Diagram - ResearchGate, accessed September 15, 2025, https://www.researchgate.net/figure/Pharmacokinetic-PK-and-pharmacodynamic-response-to-intravenous-IV-and-subcutaneous_fig1_359545848
28. Dasiglucagon Effects on QTc in Healthy Volunteers: A Randomized, Placebo-Controlled, Dose-Escalation, Double-Blind Study - PMC - PubMed Central, accessed September 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9026613/
29. Dasiglucagon Completed Phase 1 Trials for Hypoglycemia Treatment | DrugBank Online, accessed September 15, 2025, https://go.drugbank.com/drugs/DB15226/clinical_trials?conditions=DBCOND0020360&phase=1&purpose=treatment&status=completed
30. Dasiglucagon Completed Phase 2 Trials for Type 1 Diabetes Mellitus Treatment - DrugBank, accessed September 15, 2025, https://go.drugbank.com/drugs/DB15226/clinical_trials?conditions=DBCOND0029465&phase=2&purpose=treatment&status=completed
31. Dasiglucagon Recruiting Phase 1 Trials for Type 1 Diabetes Mellitus Treatment - DrugBank, accessed September 15, 2025, https://go.drugbank.com/drugs/DB15226/clinical_trials?conditions=DBCOND0029465&phase=1&purpose=treatment&status=recruiting
32. Zealand Pharma receives first FDA approval and prepares for, accessed September 15, 2025, https://www.zealandpharma.com/media/z4gnm2cw/zealand-pharma-2021-q1-interim-report.pdf
33. 214231Orig1s000 - accessdata.fda.gov, accessed September 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214231Orig1s000ClinPharmR.pdf
34. Zegalogue approved in Europe - Desang Diabetes Services, accessed September 15, 2025, https://desang.net/2024/06/zegalogue-approved-in-europe/
35. Dasiglucagon Side Effects: Common, Severe, Long Term - Drugs.com, accessed September 15, 2025, https://www.drugs.com/sfx/dasiglucagon-side-effects.html
36. Common Adverse Reactions | ZEGALOGUE® (dasiglucagon) injection - novoMEDLINK, accessed September 15, 2025, https://www.novomedlink.com/diabetes/products/treatments/zegalogue/about-zegalogue/adverse-reactions.html
37. Zegalogue, INN-dasiglucagon - European Medicines Agency, accessed September 15, 2025, https://www.ema.europa.eu/en/documents/product-information/zegalogue-epar-product-information_en.pdf
38. Dasiglucagon: Side Effects, Uses, Dosage, Interactions, Warnings - Rx List, accessed September 15, 2025, https://www.rxlist.com/dasiglucagon/generic-drug.htm
39. Dasiglucagon: First Approval - PubMed, accessed September 15, 2025, https://pubmed.ncbi.nlm.nih.gov/34047955/
40. 214231Orig1s000 | FDA, accessed September 15, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214231Orig1s000MedR.pdf
41. Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency - BioSpace, accessed September 15, 2025, https://www.biospace.com/zealand-pharma-announces-positive-chmp-opinion-for-dasiglucagon-for-treatment-of-severe-hypoglycemia-in-diabetes-from-european-medicines-agency
42. MAA submitted to the European Medicines Agency for dasiglucagon for treatment of severe hypoglycemia in diabetes - Novo Nordisk + Zealand Pharma - Medical Update Online, accessed September 15, 2025, https://medicalupdateonline.com/2023/07/maa-submitted-to-the-european-medicines-agency-for-dasiglucagon-for-treatment-of-severe-hypoglycemia-in-diabetes-novo-nordisk-zealand-pharma/
43. Zealand Pharma Announces Financial Results for the First Half of 2023., accessed September 15, 2025, https://www.zealandpharma.com/media/xgbdzasl/zealand-pharma-2023-q2h1-interim-report.pdf
44. Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency, accessed September 15, 2025, https://firstwordpharma.com/story/5862489
45. Human medicines European public assessment report (EPAR): Zegalogue, dasiglucagon, Date of authorisation: 24/07/2024, Revision: 2, Status, accessed September 15, 2025, https://efim.org/node/142428
46. Zealand Pharma Announces Global License and Development Agreement with Novo Nordisk for ZEGALOGUE® (dasiglucagon) - GlobeNewswire, accessed September 15, 2025, https://www.globenewswire.com/news-release/2022/09/07/2511078/0/en/Zealand-Pharma-Announces-Global-License-and-Development-Agreement-with-Novo-Nordisk-for-ZEGALOGUE-dasiglucagon.html
47. Novo Nordisk bolsters diabetes portfolio with deal for Zealand Pharma's Zegalogue, accessed September 15, 2025, https://firstwordpharma.com/story/5649839
48. Zealand summons Novo Nordisk to resuscitate floundering diabetes newcomer Zegalogue - Fierce Pharma, accessed September 15, 2025, https://www.fiercepharma.com/pharma/novo-nordisk-links-danish-compatriot-zealand-resuscitate-its-floundering-hypoglycemia
49. Partnering - About us - Zealand Pharma, accessed September 15, 2025, https://www.zealandpharma.com/about-us/partnering/
50. How Do Zegalogue vs Glucagon Work for Hypoglycemia Treatment? - GoodRx, accessed September 15, 2025, https://www.goodrx.com/conditions/hypoglycemia/zegalogue-vs-glucagon-for-severe-low-blood-sugar
51. Glucagon Agents Summary, accessed September 15, 2025, https://www.hhs.texas.gov/sites/default/files/documents/jan-2024-durb-agenda-item5l.pdf
52. Systematic Literature Review and Indirect Treatment Comparison of ..., accessed September 15, 2025, https://pubmed.ncbi.nlm.nih.gov/37707700/
53. Systematic Literature Review and Indirect Treatment Comparison of Three Ready-to-Use Glucagon Treatments for Severe Hypoglycemia - PMC, accessed September 15, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10570215/
54. Compare Baqsimi or Gvoke With IM Glucagon for Severe Hypoglycemia, accessed September 15, 2025, https://pharmacist.therapeuticresearch.com/en/Content/Articles/PLH/2019/Nov/Compare-Baqsimi-or-Gvoke-With-IM-Glucagon-for-Severe-Hypoglycemia
55. Dasiglucagon in Children With Congenital Hyperinsulinism Up to 1 Year of Age: Results From a Randomized Clinical Trial - Oxford Academic, accessed September 15, 2025, https://academic.oup.com/jcem/article/110/8/e2674/7908150
56. FDA declines to approve Zealand Pharma's hypoglycaemia therapy in infants, accessed September 15, 2025, https://www.pharmaceutical-technology.com/news/fda-zealand-hypoglycemia-therapy/
57. Dasiglucagon | CAS# 1544300-84-6 | Hypoglycemia - MedKoo Biosciences, accessed September 15, 2025, https://www.medkoo.com/products/44692